Schedule I → Schedule III: A Landmark Policy Shift with Important Limits

The U.S. Attorney General has formally signed a directive rescheduling marijuana, and FDA-approved marijuana products, from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). This is the most significant shift in federal drug policy in over fifty years. For our clients across industries, whether directly operating in the cannabis space or simply affected by its evolving regulatory status, understanding the precise scope of this action is essential. This Alert summarizes what has changed, what has not, and the near-term strategic implications for your business.

Background: What just happened

Under the CSA, Schedule I substances are classified as having no accepted medical use and a high potential for abuse, a designation marijuana has carried since 1970. Schedule III substances, by contrast, are recognized as having accepted medical use and a moderate-to-low potential for physical dependence. The rescheduling directive moves marijuana into this less-restricted category.

Important threshold point: This action is an executive directive, not an act of Congress. It was issued pursuant to the AG’s statutory authority under the CSA, consistent with HHS’s recommendation following an FDA review initiated in 2022. Because it is not the product of full notice-and-comment rulemaking under the Administrative Procedure Act (APA), its implementation remains subject to legal challenge and potential reversal. A formal rulemaking process with set deadlines has been ordered to run concurrently.

The Core Legal Change at a Glance

Marijuana moves from Schedule I (no recognized medical use; maximum federal restriction) to Schedule III (accepted medical use; moderate regulation). This reclassification has direct consequences for federal tax treatment, research access, and compliance risk across multiple industries, but it is not federal legalization, and the existing state-law framework remains unchanged.

What Rescheduling Does Mean: Key Implications by Sector

Cannabis Operators (Plant-Touching)

• IRC § 280E relief: Section 280E disallows ordinary business deductions for businesses trafficking Schedule I or II substances. Rescheduling to Schedule III should remove licensed operators from § 280E’s reach, potentially transforming profitability for multi-state operators and single-state licensees alike. This is the single most significant near-term financial implication. Tax counsel should be engaged immediately.
• Reduced federal criminal exposure for state-licensed activity, though full federal legality remains absent.
• Improved access to institutional capital as compliance risk perception among banks and investors softens.
• Accelerated path for clinical research, FDA-pathway products, and pharmaceutical partnerships as Schedule III research protocols are substantially less burdensome than Schedule I.
• Moral and political legitimacy: Federal acknowledgment that marijuana has recognized medical utility reframes regulatory and legislative discussions at every level.

Non-cannabis Businesses

• Pharma / Biotech / Life Sciences: Research barriers on cannabis-derived and synthetic cannabinoid compounds drop materially. This opens IP development and pipeline opportunities that were practically unavailable under Schedule I.
• Financial Institutions: The risk calculus on cannabis-related accounts, deposits, loans, and investment products changes. Compliance teams should formally revisit BSA/AML policies, credit underwriting frameworks, and existing SAR practices.
• Employers and Plan Sponsors: Drug testing policies, workers’ compensation programs, and ERISA compliance frameworks premised on Schedule I classification warrant immediate review.
• Capital Markets / Investors: Cannabis company valuations, SPAC structures, M&A representations, and earnout provisions tied to federal regulatory status require re-examination. The § 280E relief alone materially affects target EBITDA.
• Insurance Coverage determinations and underwriting criteria referencing Schedule I status should be reviewed.

What Rescheduling Does Not Mean: The Hard Limits

This is the most important section of this Alert. The following limitations remain firmly in place, and any business decision premised on their removal would be premature and legally unsound:

• Marijuana is not federally legal. Rescheduling to Schedule III is not federal legalization. Possession, distribution, and sale outside DEA-licensed frameworks remain federal criminal offenses.
• State law continues to govern state markets. States retain the right to prohibit marijuana within their borders. Rescheduling does not override a state’s authority to set its own policy, and marijuana will not become legal in states that have not authorized it.
• Banking access does not immediately change. The SAFE Banking Act has not passed. Federal depository institutions remain subject to Bank Secrecy Act and AML obligations that create friction for cannabis-related accounts. SAR filing obligations are not eliminated.
• Plant-touching operators cannot yet list on major U.S. exchanges. NYSE and NASDAQ listing standards incorporate federal law compliance requirements. Rescheduling does not clear this hurdle.
• Interstate commerce in marijuana remains federally prohibited. Rescheduling does not legalize the movement of marijuana across state lines.
• FDA does not assume immediate regulatory authority over state-licensed operators. Existing state regulatory frameworks continue to govern in-state cannabis activity.
• Decriminalization is not on the table. Rescheduling does not eliminate federal criminal penalties for unauthorized conduct involving marijuana.

Anticipated Legal Challenges and Risk Factors

Clients should not treat this directive as settled federal policy. Several categories of risk warrant attention:

Litigation risk: The rescheduling action is expected to face legal challenges, including potential litigation from anti-cannabis advocacy organizations such as Smart Approaches to Marijuana (SAM). These challenges may seek to enjoin implementation pending full APA rulemaking or challenge the procedural sufficiency of the expedited hearing ordered alongside the directive. An injunction, even a temporary one, could freeze the practical benefits of rescheduling mid-implementation.

Political risk: A change in administration could result in reversal of the directive prior to completion of formal rulemaking. Executive actions of this type are more susceptible to reversal than statutory changes. Clients making material capital or operational commitments in reliance on rescheduling must account for this in their risk analysis and deal documentation.

Regulatory ambiguity: Numerous downstream questions, including how DEA will administer Schedule III licensing for cannabis operators, how FinCEN guidance will be updated, and how the IRS will address § 280E relief retroactively, remain unanswered. Guidance is expected but has not been issued.

Action Items by Client Type

Cannabis Operators (Plant-Touching)

• Engage tax counsel immediately to assess § 280E exposure, transition year treatment, and whether amended returns or refund claims may be appropriate.
• Review financing agreements, covenants, and representations premised on Schedule I status for amendment or waiver needs.
• Do not restructure operations in anticipation of banking access or exchange-listing changes that have not materialized.
• Monitor DEA rulemaking and any injunctive proceedings; factor litigation timelines into operational planning.

Ancillary Cannabis Businesses (Non-Plant-Touching)

• Revisit M&A and investment structures; improved operator profitability post-§ 280E may shift valuations and attract previously cautious acquirors.
• Review IP portfolios and pipeline assets for cannabis-adjacent compounds that may now be commercially viable.

Financial Institutions

• Conduct a formal compliance review of cannabis-related account and lending policies with outside counsel.
• Do not eliminate SAR filing obligations based on rescheduling alone; FinCEN guidance governs, and no updated guidance has been issued.
• Begin internal analysis of credit underwriting frameworks for cannabis credits in anticipation of eventual banking reform.

Pharmaceutical / Biotech

• Assess pipeline opportunities for cannabis-derived IND filings under Schedule III research protocols.
• Consider IP strategy around formulations, delivery mechanisms, and synthetic cannabinoids.
• Evaluate partnership and licensing opportunities with established cannabis operators.

Capital Markets / Investors

• Re-underwrite cannabis positions and deal structures in light of § 280E relief implications.
• Review rep-and-warranty and earnout structures in pending M&A transactions for regulatory status assumptions.
• Monitor for exchange listing rule developments and SAFE Banking Act progress in Congress.

Our Takeaway

This is a genuine and historic inflection point. The tax implications alone, assuming § 280E relief is confirmed, represent transformative value for licensed operators. For the broader business community, the federal reframing of marijuana from a Schedule I substance with “no accepted medical use” to a Schedule III substance with recognized therapeutic value reshapes compliance posture, investor appetite, and public company disclosures across sectors.

At the same time, this is a moment that demands legal discipline. The temptation to treat rescheduling as the equivalent of federal legalization must be resisted. The legal architecture, federal prohibition, state sovereignty, exchange listing standards, banking law, and interstate commerce restrictions, remains substantially intact. The ground has shifted, but it has not been cleared.

We are actively monitoring developments across the regulatory, legislative, and litigation fronts and are available to counsel clients in all affected sectors. Please reach out to your primary contact at the firm with any questions.

Federal Marijuana Rescheduling: What it Means and What it Does Not